A Case of Pembrolizumab-Induced Pityriasis Lichenoides-Like Eruption Treated Successfully with Dupilumab

Vangelis Christou; Sharon Edwards; Andrew Affleck

doi:10.1002/jvc2.70221

A Case of Pembrolizumab-Induced Pityriasis Lichenoides-Like Eruption Treated Successfully with Dupilumab

Vangelis Christou (Lead / Corresponding author)
, Sharon Edwards
, Andrew Affleck

Undergraduate Medicine

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Abstract

Immune-checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long-standing cutaneous immune-related adverse events (cirAEs). We report a case of refractory pembrolizumab-induced pityriasis lichenoides (PL)-like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid-refractory PL-like eruptions, and may allow for continuation of ICI treatment.

Original language	English
Number of pages	4
Journal	JEADV Clinical Practice
Volume	Early View
Early online date	29 Oct 2025
DOIs	https://doi.org/10.1002/jvc2.70221
Publication status	E-pub ahead of print - 29 Oct 2025

Keywords

Dupilumab
Immune checkpoint inhibitor
Melanoma
Pityriasis lichenoides-like eruption
immune checkpoint inhibitor
pityriasis lichenoides-like eruption
melanoma
dupilumab

ASJC Scopus subject areas

Dermatology

Access to Document

10.1002/jvc2.70221Licence: CC BY

Final published version
Copyright © 2025 The Author(s). JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Final published version, 684 KBLicence: CC BY

Cite this

@article{06a58826b98f4c6da537f6062f05aa27,

title = "A Case of Pembrolizumab-Induced Pityriasis Lichenoides-Like Eruption Treated Successfully with Dupilumab",

abstract = "Immune-checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long-standing cutaneous immune-related adverse events (cirAEs). We report a case of refractory pembrolizumab-induced pityriasis lichenoides (PL)-like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid-refractory PL-like eruptions, and may allow for continuation of ICI treatment.",

keywords = "Dupilumab, Immune checkpoint inhibitor, Melanoma, Pityriasis lichenoides-like eruption, immune checkpoint inhibitor, pityriasis lichenoides-like eruption, melanoma, dupilumab",

author = "Vangelis Christou and Sharon Edwards and Andrew Affleck",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). JEADV Clinical Practice published by John Wiley \& Sons Ltd on behalf of European Academy of Dermatology and Venereology.",

year = "2025",

month = oct,

day = "29",

doi = "10.1002/jvc2.70221",

language = "English",

volume = "Early View",

}

TY - JOUR

T1 - A Case of Pembrolizumab-Induced Pityriasis Lichenoides-Like Eruption Treated Successfully with Dupilumab

AU - Christou, Vangelis

AU - Edwards, Sharon

AU - Affleck, Andrew

PY - 2025/10/29

Y1 - 2025/10/29

N2 - Immune-checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long-standing cutaneous immune-related adverse events (cirAEs). We report a case of refractory pembrolizumab-induced pityriasis lichenoides (PL)-like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid-refractory PL-like eruptions, and may allow for continuation of ICI treatment.

AB - Immune-checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long-standing cutaneous immune-related adverse events (cirAEs). We report a case of refractory pembrolizumab-induced pityriasis lichenoides (PL)-like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid-refractory PL-like eruptions, and may allow for continuation of ICI treatment.

KW - Dupilumab

KW - Immune checkpoint inhibitor

KW - Melanoma

KW - Pityriasis lichenoides-like eruption

KW - immune checkpoint inhibitor

KW - pityriasis lichenoides-like eruption

KW - melanoma

KW - dupilumab

UR - https://www.scopus.com/pages/publications/105020068954

U2 - 10.1002/jvc2.70221

DO - 10.1002/jvc2.70221

M3 - Article

VL - Early View

JO - JEADV Clinical Practice

JF - JEADV Clinical Practice

ER -

A Case of Pembrolizumab-Induced Pityriasis Lichenoides-Like Eruption Treated Successfully with Dupilumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this